Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine The ROPA-DOP Trial

被引:35
|
作者
Sharma, Kavita [1 ]
Vaishnav, Joban [1 ]
Kalathiya, Rohan [1 ]
Hu, Jiun-Ruey [1 ]
Miller, John [1 ]
Shah, Nishant [1 ]
Hill, Terence [1 ]
Sharp, Michelle [1 ]
Tsao, Allison [1 ]
Alexander, Kevin M. [1 ]
Gupta, Richa [1 ]
Montemayor, Kristina [1 ]
Kovell, Lara [1 ]
Chasler, Jessica E. [1 ]
Lee, Yizhen J. [1 ]
Fine, Derek M. [2 ]
Kass, David A. [1 ]
Weiss, Robert G. [1 ]
Thiemann, David R. [1 ]
Ndumele, Chiadi E. [1 ]
Schulman, Steven P. [1 ]
Russell, Stuart D. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD USA
关键词
acute decompensated heart failure; diuresis; dopamine; heart failure with preserved ejection fraction; worsening renal function; LOW-DOSE DOPAMINE; WORSENING RENAL-FUNCTION; FUROSEMIDE; DYSFUNCTION; PREVALENCE; INFUSION; EFFICACY; OUTCOMES; TRENDS;
D O I
10.1016/j.jchf.2018.04.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study sought to compare a continuous infusion diuretic strategy versus an intermittent bolus diuretic strategy, with the addition of low-dose dopamine (3 mg/kg/min) in the treatment of hospitalized patients with heart failure with preserved ejection fraction (HFpEF). BACKGROUND HFpEF patients are susceptible to development of worsening renal function (WRF) when hospitalized with acute heart failure; however, inpatient treatment strategies to achieve safe and effective diuresis in HFpEF patients have not been studied to date. METHODS In a prospective, randomized, clinical trial, 90 HFpEF patients hospitalized with acute heart failure were randomized within 24 h of admission to 1 of 4 treatments: 1) intravenous bolus furosemide administered every 12 h; 2) continuous infusion furosemide; 3) intermittent bolus furosemide with low-dose dopamine; and 4) continuous infusion furosemide with low-dose dopamine. The primary endpoint was percent change in creatinine from baseline to 72 h. Linear and logistic regression analyses with tests for interactions between diuretic and dopamine strategies were performed. RESULTS Compared to intermittent bolus strategy, the continuous infusion strategy was associated with higher percent increase in creatinine (continuous infusion: 16.01%; 95% confidence interval [CI]: 8.58% to 23.45% vs. intermittent bolus: 4.62%; 95% CI: -1.15% to 10.39%; p = 0.02). Low-dose dopamine had no significant effect on percent change in creatinine (low-dose dopamine: 12.79%; 95% CI: 5.66% to 19.92%, vs. no-dopamine: 8.03%; 95% CI: 1.44% to 14.62%; p = 0.33). Continuous infusion was also associated with greater risk of WRF than intermittent bolus (odds ratio [ OR]: 4.32; 95% CI: 1.26 to 14.74; p = 0.02); no differences in WRF risk were seen with low-dose dopamine. No significant interaction was seen between diuretic strategy and low-dose dopamine (p > 0.10). CONCLUSIONS In HFpEF patients hospitalized with acute heart failure, low-dose dopamine had no significant impact on renal function, and a continuous infusion diuretic strategy was associated with renal impairment. (Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction [ROPA-DOP]; NCT01901809) (C) 2018 by the American College of Cardiology Foundation.
引用
收藏
页码:859 / 870
页数:12
相关论文
共 50 条
  • [1] Randomized Evaluation of Heart Failure with Preserved Ejection Fraction Patients with Acute Heart Failure and Dopamine (Ropa-Dop) Trial
    Sharma, Kavita
    Vaishnav, Joban
    Kalathiya, Rohan
    Miller, John
    Shah, Nishant
    Hill, Terence
    Sharp, Michelle
    Tsao, Allison
    Alexander, Kevin
    Gupta, Richa
    Montemayor, Kristina
    Kovell, Lara
    Ndumele, Chiadi
    Hu, Ruey
    Chasler, Jessica
    Lee, Joan
    Grams, Morgan
    Fine, Derek
    Kass, David
    Weiss, Robert
    Thiemann, David
    Schulman, Steven
    Russell, Stuart
    JOURNAL OF CARDIAC FAILURE, 2017, 23 (11) : 831 - 831
  • [2] Combating Acute Heart Failure in the Arena Lessons From the ROPA-DOP Trial
    Ahmad, Tariq
    Felker, G. Michael
    JACC-HEART FAILURE, 2018, 6 (10) : 871 - 873
  • [3] Acute Decompensated Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction
    Sugimoto, Tadafumi
    HEART FAILURE CLINICS, 2020, 16 (02) : 201 - +
  • [4] HEART FAILURE IN PATIENTS WITH PRESERVED EJECTION FRACTION - PUMPING HEART FAILURE?
    Sokolov, A. A.
    Martsinkevich, G., I
    KARDIOLOGIYA, 2018, 58 (06) : 79 - 84
  • [5] Heart failure with preserved ejection fraction: Is this diastolic heart failure?
    Zile, MR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) : 1519 - 1522
  • [6] Heart failure with preserved ejection fraction (diastolic heart failure)
    Güder G.
    Ertl G.
    MMW - Fortschritte der Medizin, 2019, 161 (9) : 58 - 65
  • [7] Evaluation and management of heart failure with preserved ejection fraction
    Borlaug, Barry A.
    NATURE REVIEWS CARDIOLOGY, 2020, 17 (09) : 559 - 573
  • [8] Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
    Gavin A. Lewis
    Susanna Dodd
    Dannii Clayton
    Emma Bedson
    Helen Eccleson
    Erik B. Schelbert
    Josephine H. Naish
    Beatriz Duran Jimenez
    Simon G. Williams
    Colin Cunnington
    Fozia Zahir Ahmed
    Anne Cooper
    Stuart Rajavarma Viswesvaraiah
    Theresa Russell
    Paula R. McDonagh
    Christopher A. Williamson
    Nature Medicine, 2021, 27 : 1477 - 1482
  • [9] Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
    Lewis, Gavin A.
    Dodd, Susanna
    Clayton, Dannii
    Bedson, Emma
    Eccleson, Helen
    Schelbert, Erik B.
    Naish, Josephine H.
    Jimenez, Beatriz Duran
    Williams, Simon G.
    Cunnington, Colin
    Ahmed, Fozia Zahir
    Cooper, Anne
    Viswesvaraiah, Rajavarma
    Russell, Stuart
    McDonagh, Theresa
    Williamson, Paula R.
    Miller, Christopher A.
    NATURE MEDICINE, 2021, 27 (08) : 1477 - +
  • [10] Evaluation and management of heart failure with preserved ejection fraction
    Barry A. Borlaug
    Nature Reviews Cardiology, 2020, 17 : 559 - 573